Squarepoint
FENC icon

Squarepoint’s Fennec Pharmaceuticals FENC Stock Holding History

Squarepoint’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$348K Buy
56,510
+43,401
+331% +$335K ﹤0.01% 3598
2025
Q4 		$101K Buy
+13,109
New +$108K ﹤0.01% 4037
2024
Q3 		– Sell
-17,702
Closed -$108K – 4277
2024
Q2 		$108K Sell
17,702
-15,992
-47% -$133K ﹤0.01% 3782
2024
Q1 		$375K Buy
+33,694
New +$338K ﹤0.01% 3242
2023
Q2 		– Sell
-20,393
Closed -$170K – 3690
2023
Q1 		$170K Buy
+20,393
New +$189K ﹤0.01% 2857

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Squarepoint's FENC Position: Q1 2026 in Review

Squarepoint increased its Fennec Pharmaceuticals (FENC) stake by 331% in Q1 2026, buying an estimated $335K and bringing the position to 56,510 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #3598.

Squarepoint first reported a position in FENC in Q1 2023 and has held it in 5 quarters since. The position peaked at $375K in Q1 2024. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Squarepoint held 56,510 shares of Fennec Pharmaceuticals worth $348K as of Q1 2026.
  • Squarepoint bought 43,401 Fennec Pharmaceuticals shares in Q1 2026, an estimated $335K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3598 holding.
  • Squarepoint first reported a position in Fennec Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
  • Squarepoint's Fennec Pharmaceuticals position peaked at $375K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.